Sigma-Tau Pharmaceuticals, Inc. is a research-based pharmaceutical company focused on the discovery of molecules and therapies to help improve the lives of people who suffer from rare diseases.

This product information is intended for U.S. residents only. You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product outside the United States.

Research Pipeline
Development Program Indication Development Stage
EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) For enzyme replacement therapy for adenosine deaminase (ADA) deficiency in patients with severe combined immunodeficiency disease (SCID) who are not suitable candidates for or who have failed bone marrow transplantation. Phase III
STP-206 live biotherapeutic Prevention of necrotizing enterocolitis (NEC) Phase II
Xenbilox® (chenodeoxycholic acid) Capsules Treatment of cerebrotendinous xanthomatosis (CTX) NDA/Preparation